Intelligence · Clinical Pipeline
Larimar Therapeutics Pipeline
All ClinicalTrials.gov programs at Larimar Therapeutics — phase, modality, and trial IDs.
- Programs
- 3
Quick answer
Larimar Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Nomlabofusp, Placebo to Nomlabofusp
Larimar Therapeutics
Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.
1 trial -
CTI-1601
Larimar Therapeutics
Friedreich Ataxia
4 trials -
Nomlabofusp
Larimar Therapeutics
Friedreich Ataxia
1 trial
Frequently asked questions
How many pipeline programs does Larimar Therapeutics have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs